Armour Thyroid Seasonal Use Considerations

Why Thyroid Hormone Needs Change With the Seasons

Seasonal variation in thyroid function is not a clinical curiosity. Population studies show that serum TSH peaks in winter and reaches its nadir in summer, a pattern observed across geographic latitudes in both euthyroid and treated hypothyroid individuals. For patients taking Armour Thyroid, this means the dose optimized in August may leave them symptomatic by November.

A 2002 population analysis published in the Journal of Clinical Endocrinology and Metabolism found TSH levels in healthy adults were approximately 20% higher in December, January compared with July, August, even after adjusting for age and sex. [1] The mechanism involves at least three converging pathways: cold-induced thermogenesis, photoperiod-driven changes in hypothalamic TRH release, and seasonal shifts in sex steroid concentrations that alter thyroxine-binding globulin (TBG) capacity.

Cold-Induced Thermogenesis

Cold exposure activates brown adipose tissue and increases peripheral T4-to-T3 conversion via deiodinase type 2 (DIO2). The net effect is faster T3 clearance. On a fixed Armour Thyroid dose, accelerated T3 metabolism means free T3 falls more quickly between doses in cold months. Patients often report fatigue, hair thinning, and cold intolerance starting in October, several weeks before they or their clinician connects it to seasonal TSH drift.

Photoperiod and Hypothalamic TRH

Animal and human data both show that reduced daylight upregulates hypothalamic thyrotropin-releasing hormone (TRH) secretion. A study in Endocrinology demonstrated that Syrian hamsters subjected to short photoperiods increased pituitary TSH output within two weeks. [2] Human correlates are less dramatic but consistent: TSH rises between 0.3 to 0.5 mIU/L from summer to winter in populations living above 40° latitude. For a patient whose summer TSH sits at 1.8 mIU/L, a winter rise to 2.2 to 2.3 mIU/L may still be within reference range but could produce symptoms if their personal optimal is lower.

Sex Hormones and Thyroxine-Binding Globulin

Estrogen levels follow a mild seasonal pattern, rising slightly in spring and falling in late autumn in premenopausal women. Higher estrogen increases TBG, which binds more T4 and T3, temporarily reducing free fractions. Women in perimenopause on concurrent estradiol therapy face a compounded effect. The ATA 2014 guidelines explicitly note that "estrogen therapy increases TBG and may necessitate levothyroxine dose adjustment", the same logic applies to NDT. [3]

How Armour Thyroid Differs From Levothyroxine in Seasonal Contexts

Understanding the pharmacology of NDT explains why seasonal effects hit NDT users somewhat differently than levothyroxine users.

T3 Content and Short Half-Life

Each 60 mg (1 grain) Armour Thyroid tablet contains approximately 38 mcg T4 and 9 mcg T3. T3 has a half-life of roughly 19 hours, compared with T4's 6 to 7 days. That short half-life means T3 peaks and troughs are more pronounced, and any seasonal acceleration of T3 clearance is felt within days rather than weeks. Patients taking levothyroxine alone experience seasonal TSH drift more gradually because the large T4 depot buffers abrupt changes.

The Hoang 2013 Trial: What It Actually Found

The most-cited head-to-head comparison of NDT and levothyroxine is Hoang et al. (J Clin Endocrinol Metab 2013), a 16-week randomized crossover trial in 70 patients with hypothyroidism. [4] The investigators found no statistically significant difference in TSH between the two treatments (mean TSH 1.27 vs. 1.30 mIU/L). However, 49% of patients preferred NDT over levothyroxine, citing better energy, mood, and cognitive function. Body weight was 0.36 kg lower on NDT (P<0.05). The trial did not run across seasonal transitions, which is a notable gap in the literature. Seasonal pharmacokinetic differences between the two formulations remain under-studied.

Supraphysiologic T3 Ratio

The T3:T4 ratio in NDT (roughly 1:4) is four times higher than the ratio produced by the healthy human thyroid (approximately 1:14). [4] During winter, when T3 clearance accelerates, this high ratio provides a buffer of sorts, more T3 substrate is available. In summer, the same ratio risks mild T3 excess, which could manifest as palpitations, anxiety, or suppressed TSH. Clinicians should check free T3 (not just TSH) at summer monitoring visits, particularly if the patient is on doses above 90 mg/day.

Practical Dose Adjustment Protocol for Seasonal Transitions

The following stepwise framework reflects current endocrine practice patterns and the pharmacology outlined above. No single randomized trial has evaluated NDT-specific seasonal dose titration, so this guidance integrates physiologic evidence, pharmacokinetics, and the ATA 2014 guidelines. [3]

Autumn Transition (September to November)

1. Obtain TSH and free T3 at the first visit after Labor Day or equivalent early-September checkpoint.
2. If TSH has risen by more than 0.5 mIU/L from the summer baseline, increase Armour Thyroid by 15 mg/day (one-quarter grain).
3. Recheck TSH and free T3 in 6 to 8 weeks. Target TSH 0.5 to 2.0 mIU/L for most patients; adjust to the patient's prior personal optimal if known.
4. Ensure free T3 remains within the upper half of the reference range (typically 3.0 to 4.2 pg/mL in most lab assays). A free T3 below 2.8 pg/mL on a stable NDT dose in November is a signal to increase.

Spring Transition (March to May)

1. Obtain TSH and free T3 in early March.
2. If TSH has fallen below 0.5 mIU/L, or if the patient reports palpitations, heat intolerance, or insomnia, reduce Armour Thyroid by 15 mg/day.
3. Recheck in 6 to 8 weeks. If TSH remains suppressed below 0.1 mIU/L, consider reducing by an additional 15 mg or splitting the daily dose to reduce T3 peaks.
4. Women who start oral estradiol or higher-dose transdermal estrogen in spring (common with menopausal symptom management) need an earlier recheck at 4 weeks.

Mid-Cycle Stability Check

Patients stable on the same NDT dose for more than 12 months still benefit from a mid-year TSH check, even without symptoms. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) carries a cardiovascular risk signal in patients under age 65, per the 2012 Thyroid Studies Collaboration meta-analysis of 55,287 adults. [5]

Storage Considerations Across Seasons

Armour Thyroid tablets contain desiccated porcine thyroid gland. The biologic origin of the active ingredient makes storage temperature more consequential than for synthetic T4.

Heat and Humidity Degradation

The FDA-approved prescribing information for Armour Thyroid specifies storage between 15°C and 30°C (59 to 86°F), with protection from light and moisture. [6] Summer temperatures in vehicles, mailboxes, or non-air-conditioned bathrooms routinely exceed 40°C (104°F). A study of thyroid hormone tablet stability found that T3 degrades significantly faster than T4 at elevated temperatures, with measurable potency loss after 72 hours at 40°C. [7] Because NDT contains both T3 and T4, summer heat creates a disproportionate risk relative to pure T4 preparations.

Practical Storage Guidance

Patients should store NDT in a cool, dry location away from direct sunlight. A bedroom nightstand drawer or a dedicated medication cabinet away from kitchen or bathroom humidity works well. Patients who receive mail-order NDT should retrieve packages promptly and avoid allowing them to sit in summer mailboxes. Pill organizers filled more than one week in advance may increase exposure to ambient humidity and should be kept sealed.

Patient Populations Requiring Extra Seasonal Vigilance

Perimenopausal and Postmenopausal Women

Estrogen fluctuation during perimenopause directly alters TBG and free hormone fractions. A woman whose estradiol falls 40 to 60% over six months will simultaneously experience TBG reduction, meaning more free T3 and T4 become available. Combined with the summer nadir in TSH, this can push a previously stable NDT patient into mild thyrotoxicosis. Clinicians treating perimenopausal women on NDT should schedule an additional TSH check in the first six months after estrogen levels begin to decline significantly.

Patients With Adrenal Insufficiency

Increasing NDT dose in winter without assessing cortisol reserve carries risk. T3 accelerates cortisol metabolism via upregulation of 11-beta-HSD1. A patient with borderline adrenal reserve who increases NDT by 30 mg in October may experience fatigue, nausea, or hypoglycemia that mimics adrenal insufficiency. A morning cortisol or 1-mcg ACTH stimulation test is appropriate before pushing NDT above 120 mg/day in any patient with a history of adrenal stress or HPA dysfunction.

Athletes and High-Activity Individuals

Endurance athletes have higher baseline T3 turnover rates. Training volume often increases in spring and summer, which can suppress TSH even on a stable NDT dose due to exercise-driven T3 utilization. Athletes should log TSH results alongside training load data to identify patterns. A TSH below 0.3 mIU/L in a high-volume training block warrants holding the current dose rather than reducing immediately, with a repeat check after a recovery week.

Interpreting Labs in the Seasonal Context

Why TSH Alone Is Insufficient for NDT Monitoring

The standard of care for levothyroxine monitoring uses TSH as the primary endpoint. For NDT, this is inadequate on its own. Because NDT delivers a bolus of T3 with each dose, TSH is transiently suppressed for 4 to 6 hours post-ingestion, even at a clinically appropriate total daily dose. The American Thyroid Association 2014 guidelines acknowledge that "the fixed ratio of T4:T3 in desiccated thyroid extracts does not mimic normal thyroid secretion." [3] Patients should have blood drawn at a consistent time relative to dosing, ideally before the morning dose or at least 4 hours after it.

The Free T3 and Reverse T3 Pair

In winter, high physiologic stress or low caloric intake can shift T4 conversion toward reverse T3 (rT3) rather than active T3, a phenomenon sometimes called euthyroid sick syndrome or low-T3 syndrome. [8] A patient may have a normal TSH yet a low free T3 and an elevated rT3 ratio, explaining persistent fatigue despite seemingly adequate NDT dosing. Measuring free T3 and rT3 at the autumn and spring transitions provides a more complete picture than TSH alone. A free T3:rT3 ratio below 0.2 (using pg/mL:pg/mL units) has been proposed as a threshold for investigating conversion impairment, though this ratio lacks a validated clinical cutoff in published guidelines.

Lab Timing Protocol

The HealthRX medical team recommends the following lab panel at each seasonal transition visit:

• TSH (drawn before morning NDT dose)
• Free T3
• Free T4
• Reverse T3 (in patients with persistent symptoms despite normal TSH)
• Morning cortisol (if NDT dose is above 90 mg/day or patient has adrenal history)
• Ferritin (iron deficiency impairs DIO2-mediated T4-to-T3 conversion and worsens seasonal symptomatic drift)

Drug Interactions With Seasonal Relevance

Certain medications commonly adjusted or initiated at season transitions interact with NDT absorption or metabolism.

Vitamin D Supplementation

Many clinicians and patients initiate or increase vitamin D supplementation in autumn as sun exposure decreases. Vitamin D at high doses (above 5,000 IU/day) has shown modest immunomodulatory effects on thyroid autoantibody levels. [9] While this does not directly alter NDT pharmacokinetics, patients with Hashimoto's thyroiditis on NDT may see modestly lower TPO antibody titers after 3 to 6 months of vitamin D optimization, which could theoretically reduce inflammatory T3-resistance at the tissue level. The clinical magnitude is small but worth noting in symptomatic patients.

Calcium and Antacids

Calcium carbonate and aluminum-containing antacids reduce T4 and T3 absorption by forming insoluble complexes in the gut. This interaction is well-documented for levothyroxine and applies equally to NDT. In winter, patients who begin calcium supplementation for bone health should take NDT at least 4 hours before or after calcium. Absorption interference could mimic a seasonal dose insufficiency.

Bile Acid Sequestrants

Cholestyramine and colesevelam, sometimes initiated for cardiovascular risk management, bind thyroid hormones in the gut. If a patient begins a bile acid sequestrant in autumn, apparent winter hypothyroidism could be partly malabsorption rather than seasonal physiology. NDT should be taken at least 6 hours before cholestyramine in this scenario.

Talking With Patients About Seasonal Expectations

Clear expectations reduce unnecessary urgent calls and dose self-adjustment. The following talking points are consistent with the evidence reviewed here.

Patients should understand that a TSH rise of 0.3 to 0.5 mIU/L from summer to winter is expected physiology, not a medication failure. Symptoms that appear in October or November, specifically fatigue, weight gain of 1 to 2 kg, and cold sensitivity, warrant a lab check rather than self-adjustment.

Patients should also know that the converse applies in spring. A TSH drop in April, or new onset of heart palpitations, light sleep, or heat intolerance, may signal that the winter dose is now too high. A simple 6-week spring check prevents months of inadvertent mild thyrotoxicosis.

The average TSH turnaround at most commercial labs is 24 to 48 hours. Building a standing lab order into the care plan, so the patient can draw labs before calling the clinic, shortens the decision loop considerably.